NERRE THERAPEUTICS LTD

Active Stevenage

Research and experimental development on biotechnology

13 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
N

NERRE THERAPEUTICS LTD

Research and experimental development on biotechnology

Founded 19 Jan 2012 Active Stevenage, United Kingdom 13 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology

Previous Company Names

MOFO FIFTY-ONE LIMITED 19 Jan 2012 — 14 Sept 2012
Accounts Submitted 26 Feb 2026 Next due 31 Mar 2026 3 months overdue
Confirmation Submitted 10 Mar 2026 Next due 1 Mar 2027 8 months remaining
Net assets £-23M £3M 2025 year on year
Total assets £2M £4M 2025 year on year
Total Liabilities £26M £956K 2025 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

Stevenage Bioscience Catalyst Incubator Building Gunnels Wood Road Stevenage Hertfordshire SG1 2FX

Telephone

0800 000 0000

Website

www.example.com

Full company profile for NERRE THERAPEUTICS LTD (07916206), an active life sciences and medical technology company based in Stevenage, United Kingdom. Incorporated 19 Jan 2012. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jul → 30 Jun 2025
Type small
Next accounts 30 Jun 2025
Due by 31 Mar 2026 3 months overdue

Net Assets, Total Assets & Total Liabilities (2016–2025)

Cash in Bank

£2.23M

Decreased by £2.43M (-52%)

Net Assets

-£23.33M

Decreased by £2.87M (-14%)

Total Liabilities

£25.80M

Decreased by £956.21k (-4%)

Turnover

N/A

Employees

13

Decreased by 1 (-7%)

Debt Ratio

1043%

Increased by 618 (+145%)

Financial History

Revenue, profit, EBITDA and key financial figures

2025
30 Jun Year End
2024
30 Jun Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 3

Investors (9)

Investor NameInvestor SinceParticipating Rounds
Investor 3Dec 2012Series B, Series A
Investor 8Dec 2012Series A
Investor 9Dec 2012Series A

Share Capital

Share Capital

Share allotments and capital structure

1 Allotment 2,000,000 Shares £400.00m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
11 Dec 20152,000,000£400.00m£200

Officers

Officers

0 active 3 resigned
Status

No officers found

No officers found

Shareholders

Shareholders (1)

Nerre Therapeutics Holdings Limited
100.0%

Persons with Significant Control

Persons with Significant Control (0)

0 Active 1 Ceased

Advent Life Sciences Llp

Ceased 25 Jun 2021

Ceased

Group Structure

Group Structure

No group structure identified

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
12 May 2026InsolvencyLiquidation Voluntary Appointment Of Liquidator
12 May 2026InsolvencyLiquidation Voluntary Declaration Of Solvency
12 May 2026AddressChange Registered Office Address Company With Date Old Address New Address
12 May 2026ResolutionResolutions
31 Mar 2026OfficersTermination of Andrew Martin Kay as director on 31 Mar 2026
12 May 2026 Insolvency

Liquidation Voluntary Appointment Of Liquidator

12 May 2026 Insolvency

Liquidation Voluntary Declaration Of Solvency

12 May 2026 Address

Change Registered Office Address Company With Date Old Address New Address

12 May 2026 Resolution

Resolutions

31 Mar 2026 Officers

Termination of Andrew Martin Kay as director on 31 Mar 2026

Recent Activity

Latest Activity

Liquidation Voluntary Appointment Of Liquidator

3 weeks ago on 12 May 2026

Liquidation Voluntary Declaration Of Solvency

3 weeks ago on 12 May 2026

Change Registered Office Address Company With Date Old Address New Address

3 weeks ago on 12 May 2026

Resolutions

3 weeks ago on 12 May 2026

Termination of Andrew Martin Kay as director on 31 Mar 2026

2 months ago on 31 Mar 2026